Alison Hannah joins Rigel (NASDAQ: RIGL) as new EVP and Chief Medical Officer
Rhea-AI Filing Summary
Rigel Pharmaceuticals announced a leadership change in its top medical role. Alison L. Hannah, M.D. has been appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. At the same time, she resigned from Rigel’s Board of Directors, where she had served since May 2021.
Dr. Hannah has worked as a consultant to the pharmaceutical and biotechnology industry since 2000, focusing on investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc. Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel effective June 25, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective date of former CMO’s departure: June 25, 2026
Effective date of new CMO appointment: July 1, 2026
Start of industry consulting career: 2000
+1 more
4 metrics
Effective date of former CMO’s departure
June 25, 2026
Date Lisa Rojkjaer ceased serving as EVP and CMO and separated
Effective date of new CMO appointment
July 1, 2026
Date Alison L. Hannah’s role as EVP and CMO begins
Start of industry consulting career
2000
Year Alison L. Hannah began consulting on investigational cancer therapies
Board service start for Alison Hannah
May 2021
Month and year she joined Rigel’s Board of Directors
Key Terms
Executive Vice President and Chief Medical Officer, Board of Directors, separated from the Company, Emerging growth company
4 terms
Executive Vice President and Chief Medical Officer financial
"was appointed Executive Vice President and Chief Medical Officer of the Company"
Board of Directors financial
"resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
separated from the Company financial
"ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What executive leadership change did Rigel Pharmaceuticals (RIGL) announce?
Rigel Pharmaceuticals announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer. The company also disclosed that former Executive Vice President and Chief Medical Officer Lisa Rojkjaer, M.D. ceased serving in that role and separated from the company effective June 25, 2026.
Who is Alison L. Hannah, the new Chief Medical Officer at Rigel (RIGL)?
Alison L. Hannah, M.D. is Rigel’s new Executive Vice President and Chief Medical Officer. She has consulted for the pharmaceutical and biotechnology industry since 2000, directing development of investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc.
When does Alison Hannah’s appointment as Rigel (RIGL) Chief Medical Officer become effective?
Alison L. Hannah’s appointment as Executive Vice President and Chief Medical Officer becomes effective July 1, 2026. On that same date, she resigned from Rigel’s Board of Directors, transitioning from a board role to a full-time executive leadership position overseeing the company’s medical functions.
What happened to former Rigel (RIGL) Chief Medical Officer Lisa Rojkjaer?
Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel. The company’s disclosure notes only her end of service and separation, without providing additional detail on the terms or reasons for her departure.
Does Alison Hannah remain on Rigel (RIGL)’s Board of Directors after becoming CMO?
No. In connection with her appointment as Executive Vice President and Chief Medical Officer, Alison L. Hannah, M.D. resigned from Rigel’s Board of Directors effective July 1, 2026. She had been a board member since May 2021 before moving fully into the executive management team.
What is Alison Hannah’s industry background relevant to her new Rigel (RIGL) role?
Alison L. Hannah, M.D. has extensive oncology development experience. Since 2000, she has been a consultant to pharmaceutical and biotechnology companies focusing on investigational cancer therapies, and previously held senior roles as Chief Medical Officer at CytomX Therapeutics and Senior Medical Director at SUGEN, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
